We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Dupilumab‐induced Urticaria.
- Authors
Mastorino, Luca; Ortoncelli, Michela; Virginia, Bernardi; Rolla, Giovanni; Avallone, Gianluca; Cavaliere, Giovanni; Riccardo, Viola; Quaglino, Pietro; Ribero, Simone
- Abstract
Careful monitoring of the patient's condition in case of dupilumab-induced urticaria should be performed and discontinuation of the treatment should be considered. In February 2019, a male patient in his 40s affected by AD was started with bi-weekly 300 mg injection of dupilumab, loading dose of 600 mg, after unsuccessful therapeutic courses with cyclosporine and oral steroids. The patient experienced complete resolution of AD lesions during the following 18 months; a single episode of urticaria was reported during the first 4 months of treatment.
- Subjects
URTICARIA; DUPILUMAB; DIAGNOSIS; BIOTHERAPY; MONOCLONAL antibodies; ATOPIC dermatitis
- Publication
Dermatologic Therapy, 2021, Vol 34, Issue 6, p1
- ISSN
1396-0296
- Publication type
Article
- DOI
10.1111/dth.15117